Jun 11, 2026 10:46AM
Jun 11, 2026 10:45AM
Feb 23, 2026 06:28AM
Feb 17, 2026 11:01AM
Jan 28, 2026 06:42AM
Jan 20, 2026 06:39AM
Dec 8, 2025 04:15AM Genmab A/S (GMAB) PT Raised to $38 at Leerink Partners
Dec 7, 2025 07:50AM
Dec 7, 2025 07:50AM
Dec 7, 2025 07:50AM
Dec 7, 2025 07:50AM
Nov 18, 2025 11:30AM
Nov 18, 2025 11:30AM
Nov 10, 2025 06:48AM Genmab A/S (GMAB) PT Raised to $41 at H.C. Wainwright
Nov 6, 2025 11:02AM
Nov 3, 2025 09:05AM
Oct 18, 2025 06:00AM
Sep 29, 2025 01:08AM
Sep 29, 2025 01:08AM
Sep 3, 2025 08:30AM
Sep 3, 2025 08:30AM Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma
Aug 19, 2025 08:01AM
Aug 19, 2025 08:00AM
Aug 15, 2025 06:51AM
Aug 7, 2025 11:08AM
Aug 7, 2025 10:30AM
Aug 7, 2025 10:30AM
Aug 7, 2025 10:30AM Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
Aug 7, 2025 10:30AM
May 1, 2025 08:24PM
May 1, 2025 08:14PM
Mar 17, 2025 12:19PM
Mar 17, 2025 12:19PM
Feb 12, 2025 11:01AM
Dec 21, 2024 10:00AM RBC report: Biotech faces both uncertainty and growth opportunities in 2025
Dec 7, 2024 07:00PM
Sep 20, 2024 06:48AM
Sep 15, 2024 08:45AM
Aug 8, 2024 11:03AM
Jun 27, 2024 06:37AM
Jun 27, 2024 05:08AM
Jun 26, 2024 07:03PM EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
May 23, 2024 05:00PM
May 21, 2024 11:07AM
May 21, 2024 11:06AM
May 2, 2024 11:01AM
Apr 29, 2024 06:55PM
Apr 29, 2024 06:40PM
Apr 29, 2024 06:40PM FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
Apr 3, 2024 05:41AM

322,969 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All